Quantcast
Home > Quotes > MNOV
MNOV

Medicinova Inc Common Stock (MNOV) Quote & Summary Data

$11
*  
0.39
3.68%
Get MNOV Alerts
*Delayed - data as of May 21, 2019  -  Find a broker to begin trading MNOV now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    MNOV Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 11.17 / $ 10.825
Share Volume
151,630
50 Day Avg. Daily Volume
115,199
Previous Close
$ 10.61
52 Week High / Low
$ 13.37 / $ 6.6801
Market Cap
473,672,771
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
151,630
50 Day Avg. Daily Volume:
115,199

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.35

Trading Range

The current last sale of $11 is 64.67% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 11.17 $ 13.37
 Low: $ 10.825 $ 6.6801

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on developing novel, small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. Our current strategy is to focus our development activities on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Our pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.  ... More ...  



Risk Grade

Where does MNOV fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 11.10
Open Date:
May 21, 2019
Close Price:
$ 11
Close Date:
May 21, 2019


Consensus Recommendation

Analyst Info